Re-Defining Cancer: Regulations Support Biomarker-Defined Indications, But Will Science—and Advocates?
This article was originally published in RPM Report
Executive Summary
FDA is ready to re-imagine cancer defined by molecular biology rather than “body parts.” But it is going to be a “long transition” that will have important ripple effects on the structure of cancer treatment—and advocacy.